

Director's Report

National Advisory Council
for Biomedical Imaging and Bioengineering

January 19, 2021

Bruce J. Tromberg, Ph.D.
Director

National Institute of Biomedical Imaging and Bioengineering



NIBIB Council Director's Report *01-19-2021*




Jill Heemskerk
Deputy Director




David George
Associate Director



Richard Leapman
Scientific Director



Kris Kandarpa
Strategic Initiatives



Jason Ford
Executive Officer





Pam
Glikman



Alisha
Hopkins



Julia
Ringel



Asha
Storm



Ahmad El
Hendawy

NIBIB Council Director's Report *01-19-2021*

(continued)



Thank You!

Extramural Science Programs



Ahmad El-Hendawy
Scientific Program Analyst 2018-2021
Division of Interdisciplinary Training

Intramural Research Programs

Sumit Chaturvedi, Visiting Fellow (Dynamics of Macromolecular Assembly)
Yaya Cheng, Special Volunteer (Laboratory of Molecular Imaging and Nanomedicine (LOMIN))
Liangcan He, Special Volunteer (LOMIN)
Meijuan Jiang, Special Volunteer (LOMIN)
Joseph Lau, Post Doc Visiting Fellow (LOMIN)
Yuanyuan Ma, Special Volunteer (LOMIN)
Laura Reyes, Post Doc, (Quantitative Medical Imaging)
Anandakumar Shunmugavel, Post Doc (Quantitative Medical Imaging)
Guocan Yu, Visiting Fellow (LOMIN)

Office of Administrative Management

Mark Rotariu, *Senior Budget Analyst*
Chuck Benjamin, *Security SME IT*

Thank You!

Extramural Science Programs



Ahmad El-Hendawy
Scientific Program Analyst 2018-2021
Division of Interdisciplinary Training

Council Term ended May 2020
Stayed on thru Jan 2021



David Grainger PhD
University of Utah

New NIBIB Staff

Extramural Science Programs



Afrouz Anderson, Ph.D.

*Program Director – Optical Imaging
DAST*



Jennifer Jackson, Ph.D.

*Health Science Policy Analyst
OPESP*



Judy Wawira Gichoya, M.D., M.S.

*Data Scholar
DS-I Africa*



Grace Zhou

*Fellow
DDST*



Krishna Juluru, M.D.

*Presidential Innovation Fellow
OD*



Rui Carlos Sa, Ph.D.

*Data Scholar
MIDRC*

Office of Administrative Management



Kimberly Tam

Budget Analyst



Hank Durand

Grants Analyst



Munir Esmail


Program Manager



Eugene Hwang

Data Analyst

Office of Science Policy and Public Liaison



Che Figueroa-Rodriguez

Web Developer

Intramural Research Programs

Chineze Egwudo, Post Bac Fellow (Quantitative Medical Imaging)
Parinaz Fathi, Post Doc Fellow (Immuno-Engineering)
Maria Karkanitsa, Biologist Contractor (Immuno-Engineering)
Eric Krueger, Biologist Contractor (High-Resolution Optical Imaging)
Alexis Manning, Special Volunteer (Mechanobiology)
Tran Ngo, Post Bac Fellow (Immuno-Engineering)
Barbara Romero, Post Doc Fellow (Biophotonics)
Lixia Zhang, Biologist Contractor (Advanced Imaging and Microscopy)

Budget Update

FY21 Appropriations Summary

- NIH - \$42,934,000,000 (increase of \$1,250,000,000 above FY20 level, or 3% increase)
- NIBIB 410,728,000 (\$7,090,000 above FY20 enacted level of \$403,638,000, 1.8% increase)
- NIH Emergency appropriation (supplement #5): \$1.25B
 - \$100,000,000 for RADx
 - \$1.15B for research & trials on COVID-19



Budget Update: COVID-19 Funding

Coronavirus Aid, Relief, and Economic Security (CARES) Act (PL 116-136)	\$60,000,000
Care Enhancement Act (PL 116-139)	\$500,000,000
NIH Office of Director RADx ATP	\$230,000,000
Biomedical Advanced Research and Development Authority - IDDA (PSC-2020-132)	\$307,603,000
Coronavirus Response and Relief Supplemental Appropriations Act	\$100,000,000
<hr/>	
TOTAL	\$1,197,603,000

RADx Tech program now funded through FY 2021

NIBIB Base Budget FY20/21: 814,366,000

NIBIB Supplemental Budget FY20/21: 1,197,600

2-year doubling

Goal: Establish RADx as core NIBIB program for FY22+

Leadership Update



Francis Collins, M.D., Ph.D
Reappointed NIH Director

Science Appointments:

Eric Lander, PhD: OSTP Director and Presidential
Science Advisor

Alondra Nelson, Ph.D.: OSTP Deputy Director for
Science and Society

Frances H. Arnold, Ph.D., Co-Chair of the President's
Council of Advisors on Science and Technology

Maria Zuber, Ph.D., Co-Chair of the President's
Council of Advisors on Science and Technology

Funding Announcements & Opportunities

- NIH Katz Award
- NIH-NSF Smart and Connected Health
- HEAL Initiative
- NIH FIRST Award
- Music and Health
- Synthetic Biology
- DEBUT
- R21 Mechanism

New NIH Program: *Katz ESI R01*

- Investigator-initiated R01
- Early-Stage Investigators (ESI)
- No preliminary data allowed
- New research direction for PI
- Up to 5-years may be requested
- Two Katz FOAs:
 - [PAR-21-038 \(Clinical Trial Not Allowed\)](#)
 - [PAR-21-039 \(Basic Experimental Studies with Humans Required\)](#)
 - *NIBIB is not participating on PAR-21-039*



Stephen I Katz, M.D., Ph.D.
Director NIAMS 1995-2018

First due date January 26, 2021



*NIH Katz Award Committee
Co-chair, David George, Ph.D.
Member, Randy King, Ph.D.*

NSF-NIH Smart & Connected Health Program

- Successful NSF-NIH program since 2013; aligns with NIBIB programs/mission
- [NOT-OD-21-011: Notice of NIH Participation in Smart Health and Biomedical Research in the Era of Artificial Intelligence and Advanced Data Science](#)
- Developing technologies to transform health and medicine (\$300K/year, up to 4 years)
- The new program “*Smart Health and Biomedical Research in the Era of Artificial Intelligence and Advanced Data Science*”, was restructured to promote two goals of the NIH’s Strategic Plan for Data Science with 23 ICOs’ participation

Application due date February 16, 2021

Qi Duan, Ph.D.
Program Director



Information
Infrastructure

Transformative Data
Science

Novel Multimodal
Sensor System
Hardware

Effective Usability

Automating Health

Medical Image
Interpretation

HEAL Initiative: *HEAL*thy Brain & Child Development

Goal: *understand impact of fetal drug exposure, adversities on mental & behavioral health; inform intervention/prevention strategies.*

Longitudinal study: cognitive, psychosocial assessments + advanced imaging (MRI, EEG, NIRS etc.)

- 7,500 subjects to be scanned from birth to 10 years old.
- Portable imaging tech, e.g. EEG and fNIRS, for infants in motion, baby-caregiver interactions, etc.
- New imaging tech, e.g. novel fMRI and fetal ultrasound, in large-scale study.

Four FOAs:

- [RFA-DA-21-020 - Unlinked Research Project Sites \(U01\)](#)
- [RFA-DA-21-021 - Linked Research Project Sites \(U01\)](#)
- [RFA-DA-21-022 - Consortium Administrative Core \(U24\)](#)
- [RFA-DA-21-023 - Data Coordinating Center \(U24\)](#)



Shumin Wang, Ph.D.
Program Director

Letter of Intent: March 1st, 2021; Application: March 31st, 2021

Faculty Institutional Recruitment for Sustainable Transformation (FIRST)

Objective: *Create cultures of inclusive excellence*

Common Fund intends to commit **\$241 million over nine years**

[RFA-RM-20-022: FIRST Cohort \(U54 Clinical Trial Optional\)](#)

FIRST Faculty Cohort awards:

- *Hire a diverse cohort:* early-stage research faculty w/multi-level mentoring, professional development.
- *Effect systemic and sustainable institutional culture change:* address bias, equity, mentoring, and work/life issues.

[RFA-RM-20-023: FIRST Coordination & Evaluation Center \(U24 Clinical Trial Not Allowed\)](#)

FIRST Coordination and Evaluation Center:

- *Coordinate and facilitate:* development of strategies with FIRST Cohort awardees
- *Conduct a comprehensive evaluation:* impact of FIRST program

Application Due Date: March 1, 2021

Webinar **January 25, 2021, 2 - 4 pm EST.**

[https://nci.rev.vbrick.com/#/webcasts/nihfirst.](https://nci.rev.vbrick.com/#/webcasts/nihfirst)



Hannah Valantine, MD.
Chief Officer for Scientific Workforce
Diversity 2014-2019



Zeynep Erim, Ph.D.
Division Director

Music and Health FOA

[PAR-21-099: Music and Health: Understanding and Developing Music Medicine \(R21 Clinical Trial Optional\)](#)


Goals:

- Increase understanding of how music affects the brain
- Develop evidence-based music interventions to enhance health or treat specific diseases and disorders.

NIBIB Topics of interest (not limited to):

- Development of non-invasive human imaging tools and technologies to probe music's impact on the brain.
- Effects of music on the quantity of sedatives and/or analgesics as required during image-guided interventions and other minimally invasive procedures.

Guoying Liu, Ph.D.
Program Director



Synthetic Biology NOSIs

[NOT-EB-20-017: Notice of Special Interest \(NOSI\) Synthetic Biology for Biomedical Applications](#)

Goals of this Notice are to:

1. develop tools and technologies to control and reprogram biological systems.
2. apply synthetic biology approaches for the development of biomedical technologies.
3. increase the fundamental understanding of synthetic biology concepts as they relate to human health.
4. gain fundamental biological knowledge through the application of synthetic biology approaches.

The NOSI will fund R01, R21, and R35 research projects.

The NOSI expands the trans-NIH Synthetic Biology partnership from 3 ICs to 8 ICs



David Rampulla, Ph.D.

Division Director DDST

Program Director – Synthetic Biological Systems

[NOT-EB-20-022: Notice of Special Interest \(NOSI\) Administrative Supplement for Providing Travel Support for Awardees to Attend the Annual NIH Synthetic Biology Consortium Meeting \(Admin Supp\)](#)

DEBUT Design by Biomedical Undergraduate Teams Challenge

- Challenges **undergraduate teams** to design technology solutions for unmet health needs
- **Ideation** projects & projects with **Prototypes**
- Total of **\$115,000** in Prizes!
- **Submission Deadline:** June 1, 2021
- **Winners Announced:** August 25, 2021
- **Award Ceremony:** October 2021, BMES meeting

<https://www.nibib.nih.gov/research-programs/DEBUT-challenge>



Zeynep Erim, Ph.D.
Division Director



Joan Greve, Ph.D.
Program Director

NIBIB Prizes

- The Steven H. Krosnick Prize: **\$20,000**
 - Second Prize: **\$15,000**
 - Third Prize: **\$10,000**
 - HIV/AIDS Prize: **\$15,000**
- NIMHD Tech for Low-Resource Settings Prize: **\$15,000**
- New!** • NCI Technologies for Cancer Prevention, Diagnosis and Treatment Prize: **\$15,000**
- 5 Honorable Mentions: **\$1,000** each

VentureWell Prizes:

- Venture Prize: **\$15,000**
- Design Excellence Prize: **\$5,000**

NIBIB Exploratory/Developmental R21 Update

PAR-18-433: NIBIB Exploratory/Developmental Research Grant Program (R21 Clinical Trial Optional)

Key Features:

- No preliminary data allowed
- Balancing considerable risk with potential high impact research
- Expires May 8, 2021 (per issuance of NOT-EB-20-013)

NIBIB will be discontinuing this Exploratory/Developmental R21 FOA.

Alternatives include:

- R03
- Short-term R01
- Katz R01
- NIBIB Trailblazer R21




Randy King, Ph.D.
Program Director

Program Updates

- DS-I Africa
- BRAIN
- Diversity Working Group
- COVID-19

Harnessing Data Science for Health Discovery and Innovation in Africa (DS-I Africa)



Over 100 diverse group of applications received for the following FOA's:

- Open Data Science Platform and Coordinating Center (ODSP/CC)
- Ethical, Legal and Social Implications of DS-I Research
- DS-I Research Training Program
- Research Hubs



Tiffani Lash, PhD


Applications for ODSP/CC received from South Africa, Nigeria, Ghana, Uganda, Kenya, Sudan, Mali, Egypt, Tanzania, Mauritius and Rwanda

Timeline for FOA-RFA-RM-20-018




Judy Wawira, MD, MS

Applications Due
December 3, 2020



Scientific Merit Review
April/May 2021



Advisory Council Review
August 2021



Earliest Start Date
September 1, 2021



Shravani Bobde, MS

BRAIN Initiative Workshops

Dissemination of Non-Invasive Imaging Technologies

- February 18-19, 2021
- Purpose: to feature progress updates from BRAIN Initiative awardees and presentations from industry on potential pathways for follow-on dissemination.
- Agenda and Speaker Information



Shumin Wang, Ph.D.
Program Director
Co-chair

Transformative Non-Invasive Imaging Technologies

- March 9-11, 2021
- Purpose: to bring together neuroscientists, tool developers/engineers, and industry partners to identify new non-invasive functional imaging tools that could be realized in the next five to ten years.
- Agenda and Speaker Information



George Zubal, Ph.D.
Program Director

BRAIN Initiative Workshops

Dissemination of Non-Invasive Imaging Technologies

- February 18-19, 2021
- Purpose: to feature progress updates from BRAIN Initiative awardees and presentations from industry on potential pathways for follow-on dissemination.
- Agenda and Speaker Information



Shumin Wang, Ph.D.
Program Director
Co-chair



Transformative Non-Invasive Imaging Technologies



Diversity, Equity and Inclusion: *NIBIB Community*

September 2020



Gilda Barabino, Ph.D.



Roderic Pettigrew, Ph.D., MD

NIBIB Community:

- Intellectually Diverse and Embracing of New Ideas
- Problem Solvers: Blend Technology and Altruism
- Diversity Essential For Growth, Success

Co-Chairs of New Advisory Council Working Group

- Developing Diverse, Inclusive Workforce and Leadership
- Addressing Structural and Systemic Barriers, Bias
- Advancing Technology for Reducing Disparities, Improving Access

Diversity, Equity and Inclusion: *NIBIB Community*



Gilda Barabino, Ph.D.



Roderic Pettigrew, Ph.D., MD

NIBIB Community:

- Intellectually Diverse and Embracing of New Ideas
- Problem Solvers: Blend Technology and Altruism
- Diversity Essential For Growth, Success



Manu Platt, Ph.D. Associate Professor, BME, GaTech



Greg Washington, Ph.D. President, George Mason University

- Special Council Working Group, Advisory to Director
- 5 Additional external invitations in progress
- Council member participation encouraged
- Become recognized leadership voice for NIBIB community
- Coordinate with NIH-wide efforts on Diversity (UNITE)



Zeynep Erim, Ph.D.
Training Division Director

Diversity, Equity and Inclusion: *NIH-wide activity*

NIH-Wide Approach:

From December 11, 2020 Advisory Council to Director (ACD) Presentation

Create trans-NIH committees reporting to the NIH Steering Committee and reporting out to NIH Advisory Committee to the Director (ACD) to address 5 interrelated, but distinct, workstreams

- Understanding stakeholder experiences through listening and learning
- New research on health disparities/inequities
- Internal workforce
- Extramural research workforce
- Talking and communicating with our internal external stakeholders

NIBIB Representation



Zeynep Erim



Shaun Sims



Tiffany Calvert



Asha Storm

COVID-19 Pandemic

Bioengineering




- 1) Imaging and AI
- 2) Digital Health Platforms
- 3) **Diagnostic Test Technologies**

COVID-19 Supplements: *NIBIB Program*

Strong response to 3 NOSIs issued 4/10 (~5 mos, now expired)

September 2020 Council




Accomplishments (~5 months)

- MIDRC management/advisory structure (23 institutions)
- Data infrastructure, harmonization, evaluation, security and privacy requirements and processes
- Data model & data elements to enable use in AI development
- Contractual agreements with institutions interested in contributing data
- First MIDRC investigators meeting held in December 2020
- Actively link with NCATS N3C (National COVID Cohort Collaboration) for accessing COVID clinical data
- Recent RSNA publication re COVID chest images released to the public (S. Simpson et al. Radiology: Cardiothoracic Imaging 2021, 2(2))

In Progress

- 11 institutions to donate data through RSNA (RICORD) and ACR (CIRR)
- 15,000+ cases being processed for MIDRC ingestion
- 10,000+ more cases being processed for donation
- First users/data contributors meeting being planned for March 2021

1,240 COVID imaging studies available for users.



Digital Health Solutions for COVID-19

- SAFER-COVID became NIH's official return-to-work app
- More than **150K people** have used the tool to date (NIH and non-NIH)
- Activity risk calculator was **featured on CNN** (<https://safercovid.org/myrisk>)
- Tool is being configured to assist with **at-home COVID-19 testing**



Andrew Weitz, Ph.D.



Mapping a Pandemic: SARS-CoV-2 Seropositivity in the United States



Kaitlyn Sadtler, PhD, Head, Immuno-Engineering, NIBIB

300,000

250,000


200,000

150,000

100,000

50,000

0



- Undiagnosed rate in younger participants (5.9%), Black/African American (14.2%), Hispanic (6.1%), and urban residents (5.3%)
- **CDC:** Total cases as high as 8X*
- **Sadtler data similar conclusions**

~3 million total cases: *actual* >20M?

~24 million total cases, *actual*?

Cumulative US COVID-19 Cases

Mar 3, Mar 8, Mar 13, Mar 18, Mar 23, Mar 28, Apr 2, Apr 7, Apr 12, Apr 17, Apr 22, Apr 27, May 2, May 7, May 12, May 17, May 22, May 27, Jun 1, Jun 6, Jun 11, Jun 16, Jun 21, Jun 26, Jul 1, Jul 6, Jul 11, Jul 16, Jul 21, Jul 26, Jul 31, Aug 5, Aug 10, Aug 15, Aug 20, Aug 25, Aug 30, Sep 4, Sep 9, Sep 14, Sep 19, Sep 24, Sep 29, Oct 4, Oct 9, Oct 14, Oct 19, Oct 24, Oct 29, Nov 3, Nov 8, Nov 13, Nov 18, Nov 23, Nov 28, Dec 3, Dec 8, Dec 13, Dec 18, Dec 23, Dec 28, Jan 2, Jan 7, Jan 12


RADx Tech & ATP Goals

1) Expand COVID-19 Testing Technologies: *Number, Type and Access*

2) Optimize Performance: *Technologic and Operational; Match Community Needs*


Test Settings

- Home-based
- Point of Care (POC)
- Laboratory (CLIA, research)



RADx
Launch:
~250k/day

Lab > POC




POC > Lab

+ >2 million/day LFA
antigen tests unreported

<https://www.theatlantic.com/health/archive/2021/01/rapid-antigen-covid19-tests-unreported/617668/>

RADx Tech/ATP Innovation Funnel




Rolling Submissions and Selections Begin April 28, 2020

5-6 Months

Applications Started

~3000



716



137



47



25 (Tech + ATP) ~\$500M

FAST TRACK FOR ADVANCED DIAGNOSTIC TECHNOLOGIES

by end of year




Validation, Clinical Testing, Regulatory, Manufacturing, Distribution

Projects in each Phase



Mesa BioTech

Maxim



14 EUAs issued



Quidel Sophia

Yukon Swabs



Ellume



ANP


Point of Care & Home	
Visby	RTPCR
Mesa	RTPCR
Microgem	RTPCR
Talis	ISO-PCR
MatMaCorp	RTPCR
Ubiquitome	RTPCR
Quidel Sophia	An-LFA
Quidel QuickView	An-LFA
Luminostics	An-LFA
ANP	An-LFA
Ellume	An-LFA
Laboratory	
Flambeau	PCR-mobile
Fluidigm	RTPCR
Broad Inst	RTPCR
Illumina	NGS
Helix	NGS/RTPCR
Gingko	NGS/RTPCR
Sonic Healthcare	RTPCR
PathGroup	RTPCR
Aegis	RTPCR
Quanterix	SIMOA (An)
Lab Products	
Mammoth Biosci	CRISPR
Ceres Nanosciences	Beads/Conc
Yukon	Swabs



Visby Medical




Ubiquitome



Fluidigm



Luminostics




Flambeau



Mesa BioTech

Maxim



14 EUAs issued

Yukon Swabs



Quidel Sophia




Dec 15 OTC EUA

Ellume

ANP



Flambeau




Point of Care & Home	
Visby	RTPCR
Mesa	RTPCR
Microgem	RTPCR
Talis	ISO-PCR
MatMaCorp	RTPCR
Ubiquitome	RTPCR
Quidel Sophia	An-LFA
Quidel QuickView	An-LFA
Luminostics	An-LFA
ANP	An-LFA
Ellume	An-LFA
Laboratory	
Flambeau	PCR-mobile
Fluidigm	RTPCR
Broad Inst	RTPCR
Illumina	NGS
Helix	NGS/RTPCR
Gingko	NGS/RTPCR
Sonic Healthcare	RTPCR
PathGroup	RTPCR
Aegis	RTPCR
Quanterix	SIMOA (An)
Lab Products	
Mammoth Biosci	CRISPR
Ceres Nanosciences	Beads/Conc
Yukon	Swabs



Visby Medical



Ubiquitome



Fluidigm



Luminostics

RADx Leveraging NIH Proof of Concept (PoC) Network




Matt McMahon, PhD

~50 early-stage RADx-tech projects

- Project Funding
- Industry Coaching and Mentoring
- Training and Resources




RADx Impact in 2020



- ~94 million capacity in 2020
- ~48 million sold in 2020
- ~950k tests/day produced Dec 2020; ~550k/day sold
- ~14 EUAs and 1st OTC EUA
- ~190 Companies supported
- **Feb 2021:** Project millions OTC LFA tests/day
- **March 2021:** Project >2.5M tests/day

Deployment Core: CIMIT/MGH (close gap)



Bridging NIH/USG, non-profit Foundations, Academia, and Industry



Nancy Gagliano, MD
CIMIT/MGH

**“When-to-Test” modeling tool:
Match tests w/needs; evaluate
impact of risk reducing activities.**

<https://whentotest.org/>




Anette Hosoi
MIT



Paul Tessier,
CIMIT/MGH

Challenges: Screening/Surveillance LFA Performance

Wide Population Viral Loads ($n = 4774$)




Typical LOD $\sim 10^6$ Copies/mL
Sensitivity $\sim 40\%$ vs. **RTPCR** for all
(symptomatic + asymptomatic)*

Vs.


Sens/Spec $\sim 90/95\%$ for symptomatic
population (EUA: ~ 5 days post-onset)

Challenges: *Screening/Surveillance LFA Performance*

Wide Population Viral Loads ($n = 4774$)




- 1) Use LFA within ~5-7 days of symptoms
 - Elevated viral load (>90% sens, spec)
- 2) “Off Label” LFA in Asymptomatics:
 - Backup PCR w/positive in low prevalence
 - Backup PCR w/negative recently exposed
- 3) ***Sequential LFA tests***



RADx Clinical Studies Core (UMass)

Mission: Evaluate RADx platforms that advance to Phase 2 in rigorous clinical studies w/ diverse populations and settings.

- **Quidel Multisite study: UMass, UIUC, JHU in progress (n=200)**
 - Longitudinal sequential Lateral Flow Assay (LFA) assessment (2 weeks)
 - RTPCR, saliva, + viral infectiousness assay
- **LFA home testing study: UMass and Northwestern, Jan 25 (n=100)**
 - At home, Self sampling, Digital health platforms
- **LFA large population study, planning w/public health (n>200,000)**
 - Regular frequent tests break chain of transmission?



Laura Gibson, MD David McManus, MD



Clinical Study Partners




POC/Home Challenges: *Digital Health*

RADx POC Test



PCR




LFA



Cell Phone Reader

e.g. OpenRDT (Audere)

How to Use




Wearables




Digital Contact Tracing



Symptom Surveys



GATES foundation



EHR & Claims




Proof of Health Status



COVID-19 Pandemic

Summary & Future



Pandemic demands can't be addressed by "off the shelf" solutions: *Be ready with new, purpose-driven tech.*

Bioengineers are multi-lingual integrators: *Urgent need to work closely with Public Health*

Leveraging existing networks by expanding is key for speed, impact: *Build in efficiencies to counter the natural growth of bureaucracy.*

Technology development relatively easy: *Adoption, guidance, modifying human behavior for surveillance & screening are hard. **Partnerships, stakeholders!***

RADx general platform for acceleration, impact: embedding in NIBIB structure, disseminating to NIH & beyond


Thank You!



COVID19.nih.gov

NIH COVID-19 Website

- ✓ Get trusted, up-to-date, accurate information about NIH research.
- ✓ Learn about vaccines, treatments, and testing that are readily available.
- ✓ Find out how to join clinical trials and view resources from other federal agencies.



NIH National Institutes of Health
COVID-19 Research

NIH National Institute of
Biomedical Imaging
and Bioengineering